Abstract
Increasing evidence shows that the olfactory bulb is involved in blood pressure regulation in health and disease. Enhanced noradrenergic transmission in the olfactory bulb was reported in hypertension. Given that endothelins modulate catecholamines and are involved in the pathogenesis of hypertension, in the present study we sought to establish the role of the endothelin receptor type A on tyrosine hydroxylase, the rate limiting enzyme in catecholamine biosynthesis, in the olfactory bulb of DOCA-salt hypertensive rats.
Sprague-Dawley male rats, randomly divided into Control and DOCA-Salt hypertensive groups, were used to assess endothelin receptors by western blot and confocal microscopy, and their co-localization with tyrosine hydroxylase in the olfactory bulb. Blood pressure and heart rate as well as tyrosine hydroxylase expression and activity were assessed following BQ610 (ETA antagonist) applied to the brain. DOCA-Salt hypertensive rats showed enhanced ETA and decreased ETB expression. ETA co-localized with tyrosine hydroxylase positive neurons. Acute ETA blockade reduced blood pressure and heart rate and decreased the expression of total tyrosine hydroxylase and its phosphorylated forms. Furthermore, it also diminished mRNA tyrosine hydroxylase expression and accelerated the enzyme degradation through the proteasome pathway as shown by pretreatment with MG132, (20s proteasome inhibitor) intracerebroventricularly applied.
Present findings support that the brain endothelinergic system plays a major role through ETA activation in the increase of catecholaminergic activity in the olfactory bulb of DOCA-Salt hypertensive rats. They provide rationale evidence that this telencephalic structure contributes in a direct or indirect way to the hemodynamic regulation in salt dependent hypertension.
Keywords: DOCA-Salt rats, endothelin, endothelin receptors, experimental hypertension, olfactory bulb, tyrosine hydroxylase
1. Introduction
The central nervous system (CNS) has a major role in the short and long term regulation of cardiovascular activity in health and disease [1]. The solitarii tract nucleus, brain stem, the hypothalamus, the rostral ventrolateral medulla, and the locus coeruleus are well established brain structures intimately involved in cardiovascular regulation. However, despite strong evidences in the literature, the contribution of other regions like the olfactory bulb (OB) has been overlooked [2–4]. This telencephalic region is divided into the main and the accessory OB and connects with areas involved in blood pressure regulation and cardiac function, like the amygdala, piriform cortex, septum, hypothalamus, locus coeruleus and grey periaqueductal area [5–7].
The olfactory system is related to behavioral and stress responses to odor conditioning. A recent study showed the effects of predator odor fear stimuli in the modulation of autonomic activity, endocrine secretion and behavior, stressing the relevance of hypothalamic structures and showing that the signaling pathways responsible for such changes involved the OB [8]. Various studies support a clear link between the sympathetic nervous system and the OB [9]. Early works showed that olfactory stimulation correlates with respiratory and blood pressure changes in dogs [10]. Furthermore, blood pressure, breathing and sympathetic discharge increase when conscious rats are exposed to smoke whereas the opposite occurs when animals are exposed to lavender oils [9,11,12]. Changes in rat vascular and cardiac physiology correlate with norepinephrine (NE) levels in the OB, suggesting that olfactory stimulation enhances sympathetic activity and blood pressure through a multisynaptic pathway connecting the OB with brain autonomic centers [6,13]. Recent studies from our laboratory show that catecholaminergic transmission in the OB is enhanced DOCA-Salt hypertensive rats [14]. Despite growing evidence, the role of the OB in the regulation of cardiovascular function has not been fully established [15,16].
The removal of the OB significantly increases NE content and monoamine oxidase activity in the brainstem [17]. Partial or total OB removal results in behavioral, endocrine, immune, and cardiovascular changes as a consequence of modifications in brain neurotransmitters like NE, serotonin, glutamate and GABA [6,18–20]. It was also reported that a normal sympathoexcitatory response to physiological stimuli like the baroreflex is dependent on the integrity of the OBs [4].
The OB expresses all components of the endothelinergic system including the endothelin (ET) converting enzyme and both ET receptors (ETA and ETB). The ETA receptor is mainly located in the glomerular layer (GL) where the sensory information is processed [21,22]. Previous ex vivo studies from our laboratory show that ETs applied to the brain increase tyrosine hydroxylase (TH, EC 1.14.16.2) expression and activity in the OB of normotensive rats [23,24]. Although ETA and TH are expressed in the OB, their possible co-localization and the ETs-catecholamine interaction have not been yet investigated.
Hypertension is a multifactorial complex disease where genetic, dietary and environmental factors combine resulting in chronic blood pressure elevation. The role of brain catecholamines, particularly NE, in the pathogenesis of hypertension in animals and humans has been well documented. Lesions in central catecholaminergic areas attenuate hypertension in DOCA-Salt hypertensive rats and spontaneously hypertensive rats (SHR) [25,26]. Also, blood pressure elevation resulting from increased salt intake correlates with changes in brain catecholamines. Numerous studies support that the overactivity of the sympathetic nervous system and the impairment of the renin-angiotensin system are crucial events in the development of hypertension [27–29]. The DOCA-salt hypertensive rat is a neurogenic hypertensive animal model characterized by hypervolemia and hyperaldosteronism, as well as enhanced salt intake, sympathetic tone and plasma ET-1 [26, 30]. It also shows brain ET-1 mRNA overexpression and blood pressure reduction following an ETA antagonist applied to the periaqueductal grey area [31,32]. Noradrenergic activity is enhanced in the posterior hypothalamus of DOCA-Salt rats exposed to ET-1 and ET-3, which may be partially responsible for the overactivity of the sympathetic nervous system observed in this animal model [33]. In a recent study, we showed that chronic ETA blockade reduces blood pressure and prevents catecholaminergic overactivity in the OB of DOCA-salt hypertensive rats [34]. However, the interaction between ETs and catecholaminergic neurons in acute blood pressure regulation has not been assessed.
Given that noradrenergic transmission and the ET system are enhanced in the OB of DOCA-salt hypertensive rats, we sought to establish the role of ETA receptors on TH (the rate limiting enzyme and master regulator of catecholamine synthesis) and its impact on hemodynamic parameters in an attempt to advance in the knowledge of the role of the OB in salt dependent hypertension.
2. Methods
2.1. Chemicals
The following drugs and reagents were used: DOCA (MP Biomedicals, LLC OH, USA); BQ610 (American Peptide Company California, USA); MG132, N-succinyl-Leu-Leu-Val-Tyr 7-amido-4-methylcoumarin, catalase, tetrahydrobiopterin, l-tyrosine, protease inhibitor cocktail, anti-actin polyclonal antibody, anti-TH monoclonal antibody (Sigma-Aldrich, MO, USA); 3H L-tyrosine (Perkin Elmer, MA, USA); PVDF membrane (GE Healthcare, Amersham Biosciences UK); anti-TH-PSer40 polyclonal antibody, anti-TH-PSer31 polyclonal antibody, anti-TH-PSer19 polyclonal antibody, and HRP anti-mouse conjugated antibody (EMD Millipore, CA, USA); anti-ubiquitin polyclonal antibody, A/G protein, and HRP conjugated anti-rabbit antibody (Santa Cruz, TX, USA); anti-ETA polyclonal antibody and anti-ETB polyclonal antibody (Alomone Jerusalem, Israel); anti-Rabbit-Alexa488 antibody, and anti-Mouse-Alexa594 antibody (Jackson, PA, USA), quimioluminicent reaction kit (Kalium Technologies, Buenos Aires, Argentina), Tri Reagent (Molecular Research, OH, USA), RNAsin (Genbiotech, Buenos Aires, Argentina); DNAsa kit, RLVM kit, and Go-Taq (Promega, WI, USA), Oligo dT (Genbiotech, Buenos Aires, ARG), Primers (IDT, Buenos Aires, Argentina), Eva Green 20X (Biotium, CA, USA), dNTPs, and Taq Pegasus (Productos Bio-lógicos, Buenos Aires, Argentina). Other reagents were of analytical or molecular biology quality and obtained from standard sources.
2.2. Animals
Male Sprague-Dawley rats weighting between 100 and 130 gr. (from the School of Pharmacy and Biochemistry, University of Buenos Aires) were used in the experiments. Animals were housed four per cage under a 12 hs light/dark cycle, maintained with controlled temperature (22 ± 2 °C) and humidity (45 – 55%), and fed with standard commercial chow diet (Gepsa Feeds, Grupo Pilar, Pilar, Córdoba, Argentina) and water ad libitum. All experiments were performed following the principles of the Guide for Care and Use of Laboratory Animals and the International Guiding for Biomedical Research Involving Animals. The experimental protocols were approved by the Institutional Animal Care and Use Committee of the School of Pharmacy and Biochemistry, University of Buenos Aires (N° 031013-5; EXP-FYB N° 56106/13). All efforts were made to minimize the number and suffering of used rats. DOCA-salt hypertension was induced by subcutaneous injections of DOCA (15 mg/kg twice a week) and by the administration of 1% NaCl in the drinking water for five weeks. At week five animals were anesthetized and brains prepared for fluorescence microscopy studies as detailed below. Another set of animals were anesthetized at week 4 in order to place a guide cannula in the brain lateral ventricle for the administration of drugs as described below.
2.3. Experimental protocols
2.3.1. Expression of ET receptors in the OB of normotensive and DOCA-salt hypertensive rats.
At the end of the fifth week of treatment, Control and DOCA-Salt rats were euthanized by decapitation. OB were rapidly dissected and collected in cold homogenization buffer for western blot assay.
2.3.2. Expression of ET receptors and TH in the OB of normotensive and DOCA-Salt hypertensive rats by fluorescent immunohistochemistry
At week five, rats were anesthetized with urethane (1 g/kg, ip) and transcardially perfused with 0.01 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. Brains were post-fixed in 4% paraformaldehyde for 3 h at 4°C. Fixed brains were cryoprotected at 4°C with 0.01 M PBS containing 30% sucrose for 48 h. Sections (50 μm) were then cut with a cryostat (Leica CM 3050 S) and preserved for further assays. Normotensive and hypertensive brains were processed by pairs separately. The procedures were followed in a blinded way to avoid bias. Random numbers were assigned to tissues and a different operator formed the normotensive and hypertensive pairs. Incubations were made by the floating technique at room temperature with a rocking agitator.
OB slices were exposed to 0.01 M PBS containing 0.3% Triton X-100, 0.04% NaN3 and 10% normal horse serum for 1 h. Sections were then incubated overnight with the following primary antibodies: anti-ETA rabbit (1:500) and anti-TH mouse (1:10.000); or anti-ETB rabbit (1:500) and anti-TH mouse (1:10.000). Incubation with primary antibodies were followed by washes with PBS solution and exposed to secondary antibodies (anti-rabbit-Alexa 488 and anti-mouse-Alexa 594, 1:250) for 4 h in the dark. Antibodies were diluted in PBS containing 0.3% Triton X-100 and 0.04% NaN3. Histological sections were examined with a Zeiss LSM 510 confocal microscope system (Carl Zeiss, Oberkochen, Germany). The argon-krypton laser was used to excite the Alexa-488 (488 nm), He-Ne (561 nm) for the Alexa-594 fluorophores, and the diode (405 nm) for DAPI excitation. Fluorescent signal cross-talk among channels was avoided by setting image-acquisition parameters with individually labelled sections, ensuring a lack of “bleed through” to other channels. Images were taken with a 25X- LC Plan-Neofluar (oil)- NA 0.8 objective. Each picture was taken with a 1.5 um step in z axis, for a total of 10 um (8 images total) and a 1X optic zoom. From the selected area, a subregion containing the border of the glomerular lumen expressing TH positive body neurons was chosen for greater magnification (image with a 2.8X optic zoom) in order to further investigate the distribution of the TH and ET receptors.
Quantitative approaches
The images from each channel were analyzed with the ImageJ software and with a specific colocalization plugin. Initially, images were z projected with a maximum intensity and the type of the image was changed to 8 bits. Colors were then split. Threshold, quantification and colocalization were assessed in the ETA, ETB and TH images as explained below.
Threshold determination:
In the images of ETA, ETB and TH, background intensity was assessed from areas with no positive stain. To objectively define a threshold value for each color and image, 6 areas with no positive immunostaining were depicted and saved using the ROI tool. At the same time, a visual value for threshold was defined according to the investigator criteria. A factor was then calculated relating those two thresholds. After performing this measurement in all images, the factor mentioned was averaged considering the frequency of appearance for each value. The number thusly obtained was used as a weighting factor to objectively measure background in the images
Area determination:
The glomerular lumen (GLu) and the periglomerular area (PG) were depicted using the DAPI channel and saved with the ROI manager tool of the software. These sections were later reproduced in the images of ETA and TH, or ETB and TH, from the same set.
Quantification:
Measures were made for each channel in the different glomerulus and periglomerular areas (saved as ROI), limited to the threshold value previously calculated (measurement on the 6 immuno-negative areas previously depicted and saved, multiplied by the weighting factor). Fluorescence intensity and positive immunoreactive area of ETA, ETB and TH were thusly calculated for both, normotensive and hypertensive rats. Immunofluorescence intensity (au) and area percentage of positive signal was plotted into graph bars for analysis and comparison.
Colocalization:
The co-localization of TH with ET receptors was measured in the stack of confocal images z projected with maximum intensity from the different fluorophores. A co-localization plugin was used. Thresholds previously calculated for each channel during the quantification and ROIs depicted were used in this determination. Briefly, with the two images to analyze opened, after setting in the co-localization dialog which image was the red fluorophore and which the green (with the corresponding threshold for each color), two new images were created. One with the merged images and the co-localized pixels painted in white, and another image (8 bits plots) with only the pixels co-localized plotted. The later was the one used to quantify the area immune-positive for the co-localization. The periglomerular and glomerular areas were defined using the same ROIs (saved from the individual quantifications) in the corresponding images. Area percentage of co-localized signal was plotted into graph bars for analysis and comparison.
2.3.3. Effect of central ETA blockade on hemodynamic parameters and TH in the OB of normotensive and DOCA-Salt hypertensive rats.
At the end of week four, Control normotensive and DOCA-salt hypertensive rats were anesthetized with ketamine/xylazine (50/10 mg/Kg, IP) and a guide cannula was placed in the cerebral lateral ventricle. Briefly, animals under anesthesia were mounted in a stereotaxic apparatus, and a small hole was drilled through the skull. An intracranial cannula (21-gauge stainless steel, 1.5 cm in length) was placed into the left lateral ventricle by using appropriate stereotaxic coordinates (1.3 mm posterior to the bregma, 2.0 mm lateral to the midline, and 4.0 mm ventral to the skull surface). The cannula was secured by screws inserted into the surface of the bone using cyanoacrylate. Rats were placed in individual cages with free access to food and water and allowed to recover from surgery. One week later the animals were anesthetized with urethane (1 g/Kg, IP) and the femoral artery cannulated for blood pressure recording (AD Instruments PowerLab, Pty Ltd, Sydney, Australia). Following stabilization, artificial cerebrospinal fluid (aCSF) (control) or 20 μM BQ610 (selective ETA antagonist) were intracerebroventricularly (icv) applied (1 μl) and blood pressure and heart rate were recorded for 60 min. Animals were then euthanized, and OBs rapidly removed for TH activity and expression assays.
Recordings were carefully reviewed avoiding artifacts using the blood pressure module in the Lab chart software. Then data of systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and heart rate (HR) were extracted and further analyzed to compare the effect of treatments and time before drug delivery and every 10 minutes following drug injection.
2.3.4. Effect of central ETA blockade on hemodynamic parameters and TH in OB of normotensive and DOCA-salt hypertensive rats: Participation of the ubiquitin-proteasome system
In another set of animals and following the experimental procedure previously detailed, the participation of the ubiquitin-proteasome system in TH catabolism was evaluated by the icv administration of 20 μM MG132 10 min before BQ610 administration. MG132 is a synthetic tripeptide that displays a high cell penetration and inhibits reversibly the proteasome 26S complex, mainly the chymotrypsin-like activity [35]. The following groups were studied: aCSF (Control), MG132, BQ610, MG132+BQ610, DOCA-Salt, DOCA-Salt+MG132, DOCA-Salt+BQ610 and DOCA-Salt+MG132+BQ610.
2.4. Assays
2.4.1. Tyrosine hydroxylase activity
TH activity was assessed in the OBs by a radioenzymatic assay as previously detailed [36]. Results are expressed as percentage of Control ± SEM [23, 34].
2.4.2. Expression of TH and ETRs
The expression of total TH and its phosphorylated forms as well as ETRs (ETA and ETB) were assessed in the OB by western blot. Briefly, samples were separated with a 10% acrylamide gel (under denaturing and reducing conditions) after boiling for 5 min at 100°C. Proteins were then transferred to PVDF membranes, blocked with 5% non-fat milk, incubated overnight with primary antibodies at 4°C followed by secondary antibody incubation for 1 h at room temperature. Bands were detected with a quimioluminiscent kit, analyzed by densitometry and normalized to β-actin probed to the same membrane following stripping. Antibodies, working dilution and incubation periods are detailed in Table II. Results are expressed as percentage of Control ± SEM [23,33].
Table 2: Antibodies Used in Western Blot.
Antibodies | Working solution |
Incubation | |
---|---|---|---|
Primary antibodies | Anti TH | 1:2000 | 18-20 h at 4°C |
Anti β-Actin | 1:2000 | ||
Anti TH-PSerl9 | 1:2000 | ||
Anti TH-PSer31 | 1:750 | ||
Anti TH-PSer40 | 1:2000 | ||
Anti ET-A | 1:400 | ||
Anti ET-B | 1:400 | ||
Secondary antibodies | Anti-mouse (TH preincubation) | 1:4000 | 90 min at room temperature with rocking agitation |
Anti-rabbit (β-actin preincubation) | 1:4000 | ||
Anti-rabbit (TH-PSerl9 preincubation) | 1:5000 | ||
Anti-rabbit (TH-PSer31 preincubation) | 1:500 | ||
Anti-rabbit (TH-PSer40 preincubation) | 1:5000 | ||
Anti-rabbit (ET-A preincubation) | 1:2000 | ||
Anti-rabbit (ET-B preincubation) | 1:2000 |
2.4.3. TH and ETB mRNA determination
TH and ETB mRNA was determined in the OB by quantitative real time RT-PCR as previously detailed [23]. The following primers were used: TH: 5’-AGGGCTGCTGTCTTCCTAC-3’ (forward) and 5’-GCTGTGTCTGGGTCAAAGG-3 ’ (reverse); β-actin: 5’-TCTGTGTGGATTGGTGGCTCTA-3’ (forward) and 5’- CTGCTTGCTGATCCACATCTG-3’ (reverse). PCR consisted in an initial denaturalization of 5 min at 94°C; a cycling of: denaturalization at 94°C 15 sec, annealing at 54°C 30 sec and extension at 72°C 30 sec (35 times); and a melting step rising from 77°C to 95° increasing 0.3°C per sec. ETB quantification was performed using the following primers: forward 5’-CAAAGACTGGTGGCTGTTCAGTT-3’ and reverse 5’-TCAAGGCAATCTGCATACCACTT-3’. The PCR consisted in an initial denaturalization of 5 min at 94°C; a cycling of: denaturalization at 94°C 30 sec, annealing at 59.5°C 50 sec and extension at 72°C 45 sec (35 times); and a melting step rising from 70°C to 95° increasing 0.5°C per sec. Results are expressed as a percentage of Control ± SEM [23].
2.4.4. Proteasome activity
Proteasome activity was assessed as described elsewhere [35] with minor modifications. Each dissected OB was homogenized in lysis buffer (6mM HEPES, 0.3 mM EDTA, 0.6 mM DTT, 84 mM sucrose; pH 7.4) and centrifuged at 18,000 g for 10 min at 4°C. To assess proteasome activity samples were mixed with the reaction buffer (50 mM Tris-HCl, pH 7.40, 40 mM KCl, 5 mM MgCl, 2 % glycerol, 0.5 mg/ml BSA), DMSO, 60 mM ATP and 100 μM N-succinil-Leu-Leu-Val-Tyr- 7 Amido-4-metilcumarin in DMSO. Non-specific degradation was determined by adding 10 nM MG132 instead of DMSO alone. For blank reactions samples were replaced by water. Activity was measured by fluorometric detection (excitation 380 nm; emission 460 nm) for 1 h with a 6 sec interval (FlexStation III, Molecular Devices, Sunnyvale, CA, USA). The slope of fluorescence vs. time during the linear phase in each sample was normalized to its unspecific proteasome activity and total protein content. Results are expressed as percentage of control or DOCA-Salt ± SEM.
2.4.5. Co-immunoprecipitation with ubiquitin
Each sample (250 μg protein) was incubated with anti-ubiquitin antibody at 4°C for 90 min followed by the addition of AG protein-agarose and further incubated for 3 h at 4°C under shaking. Samples were then centrifuged at 1,000 g for 5 min at 4°C, pellets rinsed in PBS and resuspended in Laemmli buffer, centrifuged at 1,000g for 5 min at 4°C and freezed. Co-immunoprecipitated samples were separated the following day in a discontinuous SDS-page running polyacrylamide gel at 100 v and transferred to PDVF membranes. Bands were visualized and analyzed as previously described by measuring signal intensity over 60 kDa (TH molecular weight). Results are expressed as percentage of Control ±SEM.
2.5. Statistical Analysis
Results are expressed as mean ± SEM. Normal distribution was checked with the Shapiro-Wilk normality test. The Student’s t test was used to compare the expression of ET receptors by western blot and quantitative RT-PCR, with the Welch’s correction when variances were different. Hemodynamic parameters were analyzed by a two ways ANOVA with repeated measures over time followed by the Bonferroni post-test. TH parameters were analyzed by one-way ANOVA followed by Bonferroni post-test. Proteasome activity was assessed by the Student’s t test with Welch’s correction. In all cases p values of 0.05 or less were considered statistically significant.
3. Results
3.1. ETRs expression and co-localization with TH in OB neurons.
The expression of ETRs in the OB assessed by western blot showed that in DOCA-salt hypertensive rats ETA expression was significantly increased as compared with normotensive animals, whereas that of ETB receptors was diminished (Figures 1a and 1b). The expression of ETB receptors was also assessed by quantitative RT-PCR showing that ETB mRNA expression was also reduced in DOCA-salt hypertensive rats (Figure 1c).
ETA and TH positive neurons are highly expressed in the OB GL of normal rats [21, 37-39]. It was shown that TH positive neural cell bodies localize in the PG zone and project to the GLu [40]. Given that the GL contains glomerular structures, results were referred to the GLu or the PG area. DOCA-Salt hypertensive rats showed increased TH expression in the OB as compared to normotensive animals (Figure 2a). Strong staining was observed in the GLu and the PG area, but although TH staining was higher in the PG area rather than in the GLu in both normotensive and hypertensive rats, it was more widely distributed in the GLu. In DOCA-Salt hypertensive rats, TH positive cell bodies were increased in the PG region (Figure 2). ETA receptor staining in hypertensive animals was increased by 224.6%, in the GLu and diminished by 30.7% in the PG, though this reduction was not statistically significant (Figure 2). These findings correlate well with western blot results (Figure 1). The percentage of ETA immunoreactive area was not affected by hypertension at the glomerular or extraglomerular level. ETA receptor distribution in the OB followed the same pattern in both normotensive and hypertensive animals. The expression of ETB receptor was also similar, but the percentage of the immunoreactive area in the GLu was significantly diminished in hypertensive rats (Figure 2). Not only the intensity but also the percentage of the immunoreactive area followed the same pattern in both, GLu and PG area in normotensive and hypertensive animals. Furthermore, in both groups, the PG area showed higher ETB receptor expression.
In hypertensive rats, co-expression of ETRs and TH showed ten-fold increase in ETA/TH co-localization in the GLu without changes in the PG area, though both signals were lower in the PG area vs GLu in DOCA-Salt rats (Figure 2b). Co-localization of ETB receptor and TH was increased in the GLu of hypertensive rats (Figure 2b). Representative images are shown in Figure 2c.
3.2. Acute brain ETA blockade diminished systolic blood pressure in DOCA-Salt hypertensive rats.
Systolic blood pressure was registered before acute ETA blockade. DOCA-Salt rats showed a significant increase in systolic blood pressure (148.2 ± 4.2 mmHg) as compared to control animals (114.3 ± 6.0 mmHg) (p< 0.001). No changes were observed in body weight between the two groups (data not shown).
Blood pressure and heart rate were monitored for 60 min following ETA receptor antagonist administration. Control animals showed no changes in the haemodynamic parameters assessed following BQ610 administration (Figures 3 a-d). However, in DOCA-salt rats, the increase in systolic blood pressure was reduced by ETA blockade. The significant fall in BSP was evident at 30 min following BQ610 injection and remained diminished until the end of the experiment (Figure 3a). DBP and MAP in hypertensive animals showed a reducing trend after ETA blockade although it was not statistically significant (Figures 3 b). HR showed changes neither in normotensive nor hypertensive animals following BQ610 administration (Figure 3d). Figure 3e shows representative traces of changes in blood pressure and HR following ETA blockade.
3.3. Acute brain ETA blockade decreased the activity and phosphorylation of TH in DOCA-Salt hypertensive rats
TH activity was enhanced in the OB of hypertensive animals as previously reported [14]. Blockade of ETA induced no changes in TH activity in normotensive animals, but it reduced the enzyme activity to control values in DOCA-Salt hypertensive rats (Figure 4a). TH has four potential phosphorylation Ser-sites, three of which are intimately implicated in the activity of the enzyme (Ser19, Ser31 and Ser 40). Consistent with previous studies, the expression of TH-PSer19, TH-PSer31 and TH-PSer40 were increased in the OB of DOCA-Salt rats [14]. Blockade of ETA by BQ610, decreased the expression of the phosphorylated forms of the enzyme to control levels in hypertensive animals but induced no changes in normotensive rats (Figures 4c and 4d). Surprisingly, ETA blockade also decreased total TH protein expression in hypertensive rats (Figure 4b and c). This unexpected finding suggests TH premature degradation given the short-time exposure to the ETA antagonist.
3.4. Acute brain ETA blockade decreased total TH mRNA expression in DOCA-Salt hypertensive rats
As previously reported, TH mRNA was enhanced in hypertensive rats [14], but ETA blockade significantly decreased it (Figure 4b). Again, given the short-term exposure to the ETA antagonist, this finding suggested premature TH degradation.
3.5. Inhibition of proteasome activity prevented ETA blockade effects on hemodynamic parameters and TH activity and expression
We next evaluated whether the decrease in TH expression observed in hypertensive animals resulted from premature proteolysis. As the ubiquitin-proteasome pathway is the major route for TH degradation, following the same experimental protocol animals were pretreated with MG132 (20S proteasome inhibitor) [35,41]. Systolic blood pressure was assessed before the initiation of the study in all animals. DOCA-Salt rats showed elevated systolic blood pressure (146.9 ± 4.4 mmHg) as compared to control rats (116.1 ± 5.0 mmHg) (p< 0.001). Body weigh was not different between the two groups (data not shown).
In normotensive rats, central inhibition of the proteasome activity had no significant effect on SBP, DBP, MAP and HR (Figure 5 a-d). Nevertheless, in DOCA-Salt rats, it prevented the fall in systolic blood pressure induced by ETA blockade (Figure 5a). The decreasing trend in DBP and MAP observed after ETA blockade in hypertensive animals was inhibited by MG132. (Figures 5b-c). HR showed no changes in either group when proteasome activity was inbibited. Representative traces of changes in blood pressure and HR are shown in Figure 5e.
TH activity and expression were also assessed in the OB of animals pretreated with MG132 in the presence or absence of B1610. In control rats, proteasome inhibition increased TH activity but no changes were observed when ETA receptors were also blocked (Figure 6a). MG132 treatment did not change TH activity in the OB of hypertensive rats but it prevented the decrease induced by ETA blockade, (Figure 6a).
MG132 also prevented the decrease in total TH expression induced by BQ610 (Figures 6c and 6d). Proteasome inhibition increased TH-PSer 19 expression in normotensive rats, but BQ610 inhibited it (Figures 6c and 6d). However, in hypertensive rats, while MG132 did not affect TH-PSer19 expression it partially inhibited BQ610 response (Figures 6c and 6d). Proteasome inhibition did not cause changes in the expression of TH-PSer31 and TH-PSer40 in control animals, but in DOCA-Salt rats it increased TH-PSer31 and, although it did not modify TH-PSer40, it prevented the response of the ETA receptor activation (Figures 6c and 6d). Proteasome inhibition also inhibited BQ610 effect on TH mRNA in both normotensive and hypertensive rats (Figure 6b). Effective proteasome inhibition by MG132 in the OB was corroborated by a fluorescent substrate of the 20S subunit. Results showed that MG132 applied to the brain partially inhibited proteasome activity in the OB of normotensive and hypertensive animals (Figure 7).
3.6. ETA blockade enhanced TH ubiquitination in the OB of DOCA-Salt hypertensive rats
Present findings suggested an imbalance between TH synthesis and degradation, so we evaluated whether the enzyme was metabolized through the ubiquitin-proteasome pathway. The ubiquitin-proteasome system, through a concerted action of enzymes, mark proteins for proteasome degradation by liking them to ubiquitin. Therefore, ubiquitin-tagged TH in the OB was assessed showing that in normotensive animals, it was not changed by MG132 or ETA blockade. However, in hypertensive rats BQ610 enhanced TH ubiquitination in the OB, which was not prevented by MG132 (Figure 8).
4. Discussion
The present study advances in the knowledge of the mechanisms involved in DOCA-Salt hypertension, particularly the role of brain ETs and catecholamines in the OB. The major findings were that in DOCA-Salt hypertension: 1.- ETA expression was augmented in the OB whereas that of ETB was diminished; 2.- TH and ET receptors co-localized in the GLu of the OB; and 3.- Brain ETA blockade reduced systolic blood pressure and heart rate as well as TH activity and expression. These findings support overactivity of the endothelinergic system in the OB of DOCA-Salt hypertensive rats that leads to enhanced TH activity and expression. In addition, they further suggest an interaction between central ETs and the cardiovascular system since changes in TH induced by ETA activation in the OB were associated with hemodynamic variations, which may contribute to blood pressure elevation in salt-dependent hypertension.
In the OB, TH expresses in dopaminergic interneurons, particularly in the GL [37-39]. In accordance, TH was observed in large cell bodies in the glomerular periphery and in their varicose axons projecting to the adjacent GLu. Some TH positive neurons processes extended to two or three glomeruli. In this sense, the existence of “transglomerular” neurons, likely dopaminergic/GABAergic neurons were reported [39,40]. In DOCA-Salt rats the axonal branching of catecholaminergic neurons in the OB (defined as the positive area in the GLu) was three-fold higher than in normotensive rats and further the immnopositive area was lower in the PG area suggesting a focal distribution of the neuritis in the GLu. Conversely, in both hypertensive and normotensive animals the fluorescence intensity (indicative of TH amount) was higher in the PG area, reflecting TH accumulation within the neuronal cell bodies. Hypertensive rats showed higher TH content in both GLu and PG area supporting that DOCA-Salt rats express higher TH levels than controls. These findings correlated well with TH expression assessed by immunoblotting in the present and previous studies [14]. Higher TH expression and activity supports enhanced sympathetic outflow.
Both ET receptor subtypes are present in the brain, including the OB, but their distribution in experimental models of hypertension has not been yet investigated. We here show that, in the GL of the OB, ETA receptor was mainly found in the GLu. Fluorescence was dispersed and appeared to follow neuronal axons. Additionally, in the PG area small cells showing ETA immunoreactivity were also observed. Although ETA distribution in the OB of normotensive and hypertensive rats followed the same pattern, hypertensive rats showed enhanced immunofluorescence intensity in the Glu. These findings suggest that ETA is overexpressed in nerve fibers that integrate sensitive information. The significant increase in ETA/TH co-localization in DOCA-Salt rats is likely related to the modulation of TH activity by ETs signaling through ETA. It was surprising that hypertensive rats did not exhibit increased ETA/TH co-localization in the PG area, which would relate to a similar modulation of catecholaminergic activity by ETs in neuronal cell bodies. Nevertheless, given that TH is the rate liming enzyme in catecholamine biosynthesis which occurs in varicosities and axon terminals, increased co-localization supports a relevant role of ETs in the modulation of catecholamine transmission.
The distribution of ETB receptors in the brain has been less studied but it was reported that its mRNA expression is higher than that of ETA [42,43]. In the present study, the percentage of ETB immunoreactive area was higher in the GLu than in the PG area, while the intensity showed opposite distribution, in both normotensive and hypertensive animals. Hypertensive rats were only different in that the distribution of the immunopositive area in the GLu was lower. The apparent discrepancy regarding the expression of ETB assessed by western blot and quantitative RT-PCR may arise from the different regions assessed with each technique. Nevertheless, as the ETB receptor is associated with blood pressure lowering, the decrease of this receptor subtype in hypertensive animals is not surprising.
ET receptors and catecholamines have been found in similar brain regions such as the locus coeruleus, hypothalamus, amygdala and the GL of the OB [44–46]. To the best of our knowledge this is the first study to report in rats that ET receptors co-localize with TH in the GL of OB and that this co-localization is enhanced in hypertensive rats. In previous studies we showed that ET-1 increases TH expression in the OB and that the enzyme activity and expression is higher in DOCA-Salt rats [14,23]. Given that DOCA-Salt rats show high ET-1 levels in the CSF, our results support endogenous overstimulation of ETA in the OB, leading to enhanced brain catecholaminergic activity, which may in turn directly or indirectly induce chronic blood pressure elevation.
In the present work, following ETA blockade, SBP in hypertensive rats was significantly reduced (approximately 20 mmHg). Previous studies show that centrally applied ETs to normotensive animals increases blood pressure through ETA activation causing enhanced sympathetic outflow and arginine-vasopressin activity [45,47,48]. In DOCA-salt hypertension the degree of sympathetic overflow correlates with the level of ETs in both plasma and CSF. In this sense, the endothelinergic system is considered a key factor in salt-dependent hypertension associated with a sympathetic overflow [30,46,49,50]. In spontaneously hypertensive rats, centrally applied ETA antagonists reduce blood pressure, and nerve sympathetic activity [49]. Furthermore, ETA or ETA/ETB antagonists applied to the periaqueductal grey area, decrease blood pressure [32]. It was also shown that ETs stimulate catecholamine release from nerve endings and regulate cardiovascular function through sympathetic activation [45,46]. Likewise, we previously reported that ETs regulate noradrenergic transmission in the posterior and anterior rat hypothalamus in normotensive and DOCA-Salt rats [33,51,52]. Previous and present findings strongly support that the brain endothelinergic system regulates cardiovascular activity through an ETA-mediated sympathoexcitatory response and further suggest that this may contribute to maintain blood pressure chronically elevated.
Hypertensive animals showed higher TH activity and expression in the OB than normotensive rats as previously reported [14]. DOCA-Salt rats show alterations in the brain endothelinergic system and, also, the central administration of ETs increases catecholaminergic activity in the OB. In accordance, we observed that hypertensive rats expressed higher ETA expression and ETA/TH co-localization, and further that ETA blockade decreased TH activity and expression. The increase in TH activity and expression in the OB would be a long-term response sustained by ETs up-regulation. These peptides activate various transcription factors, some of which bind to the promotor region of the TH gene [53–55]. In this sense, preliminary studies from our laboratory show that ET-1 and ET-3 increase CREB and c-fos expression in the OB of normotensive rats. Taken together, these findings would explain the higher increase in TH mRNA in the OB of hypertensive rats.
An interesting finding was that acute ETA blockade decreased TH mRNA and protein to control levels. The short exposure to the ETA antagonist, suggested the activation of a TH degrading mechanism. Degradation of TH occurs through different mechanisms including lysosomal and chymotrypsin pathways, but the major route is the ubiquitin-proteasome system [35,56–58]. Proteasome inhibition induced no changes in blood pressure or heart rate either in normotensive or hypertensive animals, but it prevented the hypotensive effect of BQ610 in DOCA-Salt rats. MG132 administration augmented TH activity in the OB of normotensive rats but considering that the enzyme is equally active in normotensive animals treated with vehicle or MG132+BQ610, and less with MG132 alone, proteasome inhibition would evidence that the antagonist forces the response reducing the activity of the enzyme. The expression of total TH and its phosphorylated forms were in line with this consideration. Proteasome inhibition significantly increased TH-PSer19 and TH mRNA, that were not reflected on TH protein content likely due to the short time exposure [59,60]. The ubiquitin-proteasome system is also in the cell nucleus where it not only degrades proteins, but it also regulates mRNA levels. Thus, proteasome inhibition affects mRNA stability and its translocation to the cytoplasm among other reported functions [56,58]. TH linked to ubiquitin showed not changes in normotensive animals, in line with TH protein expression. In hypertensive rats, proteasome inhibition did not affect TH. Early studies reported that DOCA-Salt hypertensive rats exhibited higher proteasome content and activity than normotensive animals. Accordingly, we showed that hypertensive rats were more sensible to proteasome inhibition. A recent report showed in multiple myeloma cells that ET-1 through ETB receptors induces proteasome overregulation which confers resistance to inhibitory agents [61]. These findings, and the fact that DOCA-Salt rats show higher ET-1 levels in the CSF, would explain the finding that MG132 alone had no effect on TH activity in these animals. In accordance, proteasome inhibition did not modify the expression of total TH or its phosphorylated forms, except for TH-PSer31. Given that the ubiquitin-proteasome system degrades mainly TH phosphorylated at Ser 19 and Ser40 sites, the implication of this finding is presently unknown [56,60]. Blockade of ETA reduced TH activity in hypertensive animals which was prevented by MG132. A similar behavior was observed when the phosphorylated forms of the enzyme or TH mRNA were assessed. In summary, these observations suggest that proteasome inhibition would contribute to ETA blockade response in hypertensive rats.
Proteasome inhibition induced a slight increase (27%) in ubiquitin-linked TH in the OB of hypertensive animals in line with decreased proteasome activity. However, concomitant ETA blockade induced a significant accumulation of ubiquitin-TH (51%). Given the basal proteasome activity, the level of ubiquitin-TH in DOCA-Salt rats, and the steady state of this system in the OB, a disruption like an ETA receptor blockade, may accumulate a higher amount of ubiquitin-TH. However, as BQ610 was acutely administered, it is likely that the system fails to compensate the destabilization in response to ETA blockade, increasing ubiquitin-TH. Additionally, ETA blockade may enhance ET-1 local concentration, triggering ETB activation, which, in turn, may up-regulate the proteasome activity [61]. Taken together, the amount of a protein linked to ubiquitin would result from the kinetics of each reaction and the underlying signal transduction pathways.
Though not fully understood, evidence strongly supports a close relationship between the OB and the cardiovascular function. Changes in the vascular and cardiac function impact on various neurotransmitters including catecholamines in the OB [6]. The integrity of OB is crucial to elicit a normal excitatory response to physiological stimuli and their bilateral removal modifies blood pressure and heart rate [2,3,18]. Unpublished observations from our laboratory show that bilateral bulbectomy diminishes systolic blood pressure in DOCA-Salt rats but not in normotensive animals. Furthermore, BQ610 applied to the OB of DOCA-Salt animals diminishes systolic blood pressure as observed in the present study.
The OB connect with major brain areas involved in the regulation of cardiovascular function. The main OB projects to the piriform cortex, amygdala and entorhinal cortex, whereas the accessory OB projects to the dorsal olfactory tract, amygdala and stria terminalis. In turn, some of these regions connect with the posterior and anterior hypothalamus as well as the preoptic area [6,18,25]. Findings suggest that the endothelinergic system in the OB may play a relevant role in the central regulation of cardiovascular function through the sympathetic nervous system in health and disease.
To our knowledge, there are no reports in the literature that relate smell to salt intake in animal models of hypertension. An interesting finding is that the olfactory mucosa expresses high affinity mineralocorticoid receptors [62]. It was also shown that the loss of olfactory performance can be a consequence of the lack of sodium [63]. These data suggest a relationship between smell, sodium intake and cardiovascular function.
In summary, the present study advances in the knowledge of the central mechanisms involved in DOCA-Salt hypertension, focusing on the regulation of catecholamines by ETs in the OB. Figure 9 depicts the proposed mechanism. The higher expression of ETA in the olfactory glomeruli of hypertensive rats would enhance TH expression and activity thus leading in a direct or indirect way to sympathetic overflow and hypertension. The acute ETA blockade reveals the relevance of this mechanism in the maintenance of chronic blood pressure elevation. Present findings give further support to the role of the OB in the regulation of cardiovascular function in hypertension. Increasing evidence supports an association between the OB and cardiovascular impairment. The loss of smell in humans correlates with higher salt intake, which enhances the risk of hypertension. Furthermore, a close relationship exists between cardiovascular diseases and depression, and further depression and the OB. In this context, our results support the relevance of the OB in the regulation of chronic blood pressure elevation and the strong contribution of endothelins. New insights into the pathophysiological mechanisms underlying salt-dependent hypertension may help to design new strategies or drugs for this disease which is a major global health concern.
Table 1: Antibodies Used in Fluorescence Microscopy.
Antibody | Manufacturer | Working solution |
Incubation |
---|---|---|---|
Anti-ETA | Alomone, Jerusalem, ISR | 1:500 | 18-20 h in rocking agitation |
Anti-TH | Sigma, Missouri, USA | 1:10000 | |
Anti-Rabbit-Alexa488 | Jackson, Pensilvania, USA |
1:250 | 4 h in rocking agitation and light protected |
Anti-Mouse-Alexa594 | Jackson, Pensilvania, USA |
1:250 | |
DAPI | Sigma, Missouri, USA | 1:20000 | Last 5 min of secondary antibody incubation |
Anti-ETA | Alomone, Jerusalem, ISR | 1:500 | 18-20 h in rocking agitation |
Anti-TH | Sigma, Missouri, USA | 1:10000 | |
Anti-Rabbit-Alexa488 | Jackson, Pensilvania, USA |
1:250 | 4 h in rocking agitation and light protected |
Anti-Mouse-Alexa594 | Jackson, Pensilvania, USA |
1:250 | |
DAPI | Sigma, Missouri, USA | 1:20000 | Last 5 min of secondary antibody incubation |
Highlights.
The pathophysiological mechanisms underlying hypertension still remain unclear but brain endothelins are thought to play a key role;
Increasing evidence supports an association between the olfactory bulb and cardiovascular impairment;
Enhanced endothelin type A receptors and colocalization with tyrosine hydroxylase in olfactory bulbs occurs in DOCA-salt hypertension;
Blockade of endothelin type A receptors results in the decrease of blood pressure and accelerated tyrosine hydroxylase degradation;
The interaction of endothelins and catecholamines in the olfactory bulbs would contribute to the genesis of salt-dependent hypertension.
Acknowledgement
We thank Mónica Navarro and Gabriela Nocetti for their excellent technical assistance.
Grant support list
This work was supported by CONICET grant PIP 112-201101-00570 (MSV and LGB), ANPCyT grant PICT 2015-2030 (MSV), UBA grant UBACyT 20020100100695 (MSV and LGB) and NIH R01HL112225 (JS). Some of the experiments were carried out under a grant funded by the Bunge and Born Foundation and the Fulbright Commission (MJG).
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
5. References
- [1].Dampney RAL, Central neural Control of the cardiovascular system: current perspectives, Adv. Physiol. Educ. 40 (2016) 283–296. 10.1152/advan.00027.2016 [DOI] [PubMed] [Google Scholar]
- [2].Grippo AJ, Johnson AK, Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models., Stress. 12 (2009) 1–21. 10.1080/10253890802046281 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Kawasaki H, Watanabe S, Ueki S, Changes in blood pressure and heart rate following bilateral olfactory bulbectomy in rats., Physiol. Behav. 24 (1980) 51–56. 10.1016/0031-9384(80)90013-X. [DOI] [PubMed] [Google Scholar]
- [4].Moffitt JA, Grippo AJ, Holmes PV, Johnson AK, Olfactory bulbectomy attenuates cardiovascular sympathoexcitatory reflexes in rats., Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H2575–2583. 10.1152/ajpheart.00164.2002 [DOI] [PubMed] [Google Scholar]
- [5].Kawasaki H, Watanabe S, Ueki S, Potentiation of pressor and behavioral responses to brain stimulation following bilateral olfactory bulbectomy in freely moving rats., Brain Res. Bull. 5 (1980) 711 10.1016/0361-9230(80)90210-5 [DOI] [PubMed] [Google Scholar]
- [6].Kelly JP, Wrynn AS, Leonard BE, The olfactory bulbectomized rat as a model of depression: an update., Pharmacol. Ther. 74 (1997) 299–316. 10.1016/S0163-7258(97)00004-1 [DOI] [PubMed] [Google Scholar]
- [7].Bader A, Klein B, Breer H, Strotmann J, Connectivity from OR37 expressing olfactory sensory neurons to distinct cell types in the hypothalamus, Front. Neural Circuits. 6 (2012) 84 10.3389/fncir.2012.00084 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Takahashi LK, Sullivan RM, Rosen JB, Olfactory systems and neural circuits that modulate predator odor fear, 8 (2014) 72 10.3389/fnbeh.2014.00072 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Nagai K, Niijima A, Horii Y, Shen J, Tanida M, Olfactory stimulatory with grapefruit and lavender oils change autonomic nerve activity and physiological function., Auton. Neurosci. 185 (2014) 29–35. 10.1016/j.autneu.2014.06.005 [DOI] [PubMed] [Google Scholar]
- [10].Allen W, Olfactory and trigeminal conditioned reflexes in dogs, Am. J. Physiol. Content. 118 (1937) 532–540. 10.1152/ajplegacy.1937.118.3.532 [DOI] [Google Scholar]
- [11].Nakamura T, Hayashida Y, Autonomic cardiovascular responses to smoke exposure in conscious rats., Am. J. Physiol. 262 (1992) R738–745. 10.1152/ajpregu.1992.262.5.R738 [DOI] [PubMed] [Google Scholar]
- [12].Nagai M, Wada M, Usui N, Tanaka A, Hasebe Y, Pleasant odors attenuate the blood pressure increase during rhythmic handgrip in humans., Neurosci. Lett. 289 (2000) 227–229. 10.1016/S0304-3940(00)01278-7 [DOI] [PubMed] [Google Scholar]
- [13].Shen J, Niijima A, Tanida M, Horii Y, Maeda K, Nagai K, Olfactory stimulation with scent of lavender oil affects autonomic nerves, lipolysis and appetite in rats., Neurosci. Lett. 383 (2005) 188–193. 10.1016/j.neulet.2005.04.010 [DOI] [PubMed] [Google Scholar]
- [14].Abramoff T, Guil MJ, Morales VP, Hope SI, Soria C, Bianciotti LG, Vatta MS, Enhanced assymetrical noradrenergic transmission in the olfactory bulb of deoxycorticosterone acetate-salt hypertensive rats., Neurochem. Res. 38 (2013) 2063–2071. 10.1007/s11064-013-1114-0 [DOI] [PubMed] [Google Scholar]
- [15].Kiecolt-Glaser JK, Graham JE, Malarkey WB, Porter K, Lemeshow S, Glaser R, Olfactory influences on mood and autonomic, endocrine, and immune function., Psychoneuroendocrinology. 33 (2008) 328–339. 10.1016/j.psyneuen.2007.11.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Köteles F, Babulka P, Role of expectations and pleasantness of essential oils in their acute effects., Acta Physiol. Hung. 101 (2014) 329–340. 10.1556/APhysiol.101.2014.3.8 [DOI] [PubMed] [Google Scholar]
- [17].Pohorecky LA, Zigmond MJ, Heimer L, Wurtman RJ, Olfactory bulb removal: effects on brain norepinephrine., Proc. Natl. Acad. Sci. U. S. A. 62 (1969) 1052–1055. 10.1073/pnas.62.4.1052 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [18].Song C, Leonard BE, The olfactory bulbectomised rat as a model of depression, Neurosci. Biobehav. Rev. 29 (2005) 627–647. 10.1016/j.neubiorev.2005.03.010. [DOI] [PubMed] [Google Scholar]
- [19].Maturana MJ, Pudell C, Targa ADS, Rodrigues LS, Noseda ACD, Fortes MH, Dos Santos P, Da Cunha C, Zanata SM, Ferraz AC, Lima MMS, REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy., Mol. Neurobiol. 51 (2015) 349–360. 10.1007/s12035-014-8721-x [DOI] [PubMed] [Google Scholar]
- [20].Thakare VN, Aswar MK, Kulkami YP, Patil RR, Patel BM, Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response, Physiol. Behav. 179 (2017) 401–410. 10.1016/j.physbeh.2017.07.010 [DOI] [PubMed] [Google Scholar]
- [21].Kohzuki M, Chai SYY, Paxinos G, Karavas A, Casley DJJ, Johnston CII, Mendelsohn FAOA, Localization and characterization of endothelin receptor binding sites in the rat brain visualized by in vitro autoradiography4, Neuroscience. 42 (1991) 245–260. 10.1016/0306-4522(91)90162-H [DOI] [PubMed] [Google Scholar]
- [22].Warner TD, Budzik GP, Matsumoto T, Mitchell JA, Förstermann U, Murad F, Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA., Br. J. Pharmacol. 106 (1992) 948–952. 10.1111/j.1476-5381.1992.tb14440.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- [23].Nabhen SL, Morales VP, Guil MJ, Höcht C, Bianciotti LG, Vatta MS, Mechanisms involved in the long-term modulation of tyrosine hydroxylase by endothelins in the olfactory bulb of normotensive rats., Neurochem. Int. 58 (2011) 196–205. 10.1016/j.neuint.2010.11.016 [DOI] [PubMed] [Google Scholar]
- [24].Nabhen SL, Guil MJ, Saffioti N, Morales VP, Bianciotti LG, Vatta MS, Calcium-dependent mechanisms involved in the modulation of tyrosine hydroxylase by endothelins in the olfactory bulb of normotensive rats., Neurochem. Int. 62 (2013) 389–398. 10.1016/j.neuint.2013.01.018 [DOI] [PubMed] [Google Scholar]
- [25].Oparil S, Chen Y-F, Berecek K, Calhoun D, Wyss J, Oparil J, Chen Y-F, Berecek K, Calhoun D, Wyss S, Oparil S, Chen Y-F, Berecek K, Calhoun D, Wyss J, Oparil J, Chen Y-F, Berecek K, Calhoun D, Wyss S, The role of the Central Nervous System in Hypertension, in: Hypertens. Pathophysiol. Diagnosis Manegment, Second, 1995: pp. 713–739. [Google Scholar]
- [26].Basting T, Lazartigues E, DOCA-Salt Hypertension: an Update, Curr. Hypertens. Rep. 19 (2017) 32 10.1007/s11906-017-0731-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [27].Khor S, Cai D, Hypothalamic and inflammatory basis of hypertension, Clin. Sci. 131 (2017) 211–223. 10.1042/CS20160001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [28].de Morais SDB, Shanks J, Zucker IH, Integrative Physiological Aspects of Brain RAS in Hypertension, Curr. Hypertens. Rep. 20 (2018) 10 10.1007/s11906-018-0810-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [29].Parati G, Esler M, The human sympathetic nervous system: Its relevance in hypertension and heart failure, Eur. Heart J. 33 (2012) 1058–1066. 10.1093/eurheartj/ehs041 [DOI] [PubMed] [Google Scholar]
- [30].Yemane H, Busauskas M, Burris SK, Knuepfer MM, Neurohumoral mechanisms in deoxycorticosterone acetate (DOCA)-salt hypertension in rats., Exp. Physiol. 95 (2010) 51–55. 10.1113/expphysiol.2008.046334 [DOI] [PubMed] [Google Scholar]
- [31].Naruse M, Takagi S, Tanabe A, Naruse K, Adachi C, Yoshimoto T, Seki T, Takano K, Augmented expression of tissue endothelin-1 messenger RNA is a common feature in hypertensive rats., J. Cardiovasc. Pharmacol. 36 (2000) S195–S197. 10.1097/00005344-200036001-00059 [DOI] [PubMed] [Google Scholar]
- [32].Di Filippo C, D’Amico M, Piegari E, Rinaldi B, Filippelli A, Rossi F, Local administration of ETA (but not ETB) blockers into the PAG area of the brain decreases blood pressure of DOCA-salt rats., Naunyn. Schmiedebergs. Arch. Pharmacol. 366 (2002) 123–126. 10.1007/s00210-002-0566-6 [DOI] [PubMed] [Google Scholar]
- [33].Abramoff T, Guil MJ, Morales VP, Hope SI, Höcht C, Bianciotti LG, Vatta MS, Involvement of endothelins in deoxycorticosterone acetate-salt hypertension through the modulation of noradrenergic transmission in the rat posterior hypothalamus., Exp. Physiol. 100 (2015) 617–627. 10.1113/EP085230 [DOI] [PubMed] [Google Scholar]
- [34].Cassinotti LR, Guil MJ, Schöller MI, Navarro MP, Bianciotti LG, Vatta MS, Chronic Blockade of Brain Endothelin Receptor Type-A (ETA) Reduces Blood Pressure and Prevents Catecholaminergic Overactivity in the Right Olfactory Bulb of DOCA-Salt Hypertensive Rats., Int. J. Mol. Sci. 19 (2018) 660 10.3390/ijms19030660 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [35].Carbajosa NAL, Corradi G, Verrilli MAL, Guil MJ, Vatta MS, Gironacci MM, Gironacci MM, Tyrosine Hydroxylase Is Short-Term Regulated by the Ubiquitin- Proteasome System in PC12 Cells and Hypothalamic and Brainstem Neurons from Spontaneously Hypertensive Rats: Possible Implications in Hypertension, PLoS One. 10 (2015) e0116597 10.1371/journal.pone.0116597 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [36].Reinhard JF, Smith GK, Nichol CA, A rapid and sensitive assay for tyrosine-3- monooxygenase based upon the release of 3H2O and adsorption of [3H]-tyrosine by charcoal., Life Sci. 39 (1986) 2185–2189. 10.1016/0024-3205(86)90395-4 [DOI] [PubMed] [Google Scholar]
- [37].Kosaka T, Kosaka K, Structural Organization of the Glomerulus in the Main Olfactory Bulb, Chem. Senses. 30 (2005) i107–i108. 10.1093/chemse/bjh137 [DOI] [PubMed] [Google Scholar]
- [38].Nagayama S, Homma R, Imamura F, Neuronal organization of olfactory bulb circuits., Front. Neural Circuits. 8 (2014) 98 10.3389/fncir.2014.00098 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [39].Toida K, Kosaka K, Aika Y, Kosaka T, Chemically defined neuron groups and their subpopulations in the glomerular layer of the rat main olfactory bulb-IV. Intraglomerular synapses of tyrosine hydroxylase-immunoreactive neurons, Neuroscience. 101 (2000) 11–17. 10.1016/S0306-4522(00)00356-0 [DOI] [PubMed] [Google Scholar]
- [40].Kosaka T, Kosaka K, Neuronal organization of the main olfactory bulb revisited, Anat. Sci. Int. 91 (2016) 115–127. 10.1007/s12565-015-0309-7 [DOI] [PubMed] [Google Scholar]
- [41].Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Günther C, Baumann G, Stangl V, Stangl K, Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system., Hypertension. 51 (2008) 302–308. 10.1161/HYPERTENSIONAHA.107.097816 [DOI] [PubMed] [Google Scholar]
- [42].Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ, Endothelin, Pharmacol. Rev. 68 (2016) 357–418. 10.1124/pr.115.011833 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [43].Kurokawa K, Yamada H, Ochi J, Topographical distribution of neurons containing endothelin type A receptor in the rat brain., J. Comp. Neurol. 389 (1997) 348–360. [DOI] [PubMed] [Google Scholar]
- [44].Sluck JM, Lin RCS, Katolik LI, Jeng AY, Lehmann JC, Endothelin converting enzyme-1-, endothelin-1-, and endothelin-3-like immunoreactivity in the rat brain, Neuroscience. 91 (1999) 1483–1497. 10.1016/S0306-4522(98)00692-7 [DOI] [PubMed] [Google Scholar]
- [45].Kuwaki T, Kurihara H, CAO WH, Kurihara Y, Unekawa M, YAZAKI Y, Kumada M, Physiological role of brain endothelin in the central autonomic Control: from neuron to knockout mouse., Prog. Neurobiol. 51 (1997) 545–579. 10.1016/S0301-0082(96)00063-9 [DOI] [PubMed] [Google Scholar]
- [46].Kohan DE, Rossi NF, Inscho EW, Pollock DM, Regulation of blood pressure and salt homeostasis by endothelin., Physiol. Rev. 91 (2011) 1–77. 10.1152/physrev.00060,2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [47].Chen A-D, Xiong X-Q, Gan X-B, Zhang F, Zhou Y-B, Gao X-Y, Han Y, Endothelin-1 in paraventricular nucleus modulates cardiac sympathetic afferent reflex and sympathetic activity in rats., PLoS One. 7 (2012) e40748 10.1371/journal.pone.0040748 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [48].Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ, Role of endothelin-1 in clinical hypertension: 20 years on, 52 (2008) 452–459. 10.1161/HYPERTENSIONAHA.108.117366 [DOI] [PubMed] [Google Scholar]
- [49].Nakamura K, Sasaki S, Moriguchi J, Morimoto S, Miki S, Kawa T, Itoh H, Nakata T, Takeda K, Nakagawa M, Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP., J. Cardiovasc. Pharmacol. 33 (1999) 876–882. 10.1097/00005344-199906000-00007 [DOI] [PubMed] [Google Scholar]
- [50].Zicha J, Dobešova Z, Vokurková M, Rauchová H, Hojná S, Kadlecová M, Behuliak M, Vaněčková I, Kuneš J, Age-dependent salt hypertension in Dahl rats: fifty years of research., Physiol. Res. 61 Suppl 1 (2012) S35–87. http://www.ncbi.nlm.nih.gov/pubmed/22827876 (accessed June 13, 2017). [DOI] [PubMed] [Google Scholar]
- [51].di Nunzio AS, Jaureguiberry MS, Rodano V, Bianciotti LG, Vatta MS, Endothelin-1 and -3 diminish neuronal NE release through an NO mechanism in rat anterior hypothalamus., Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002) R615–22. 10.1152/ajpregu.00026.20Q2 [DOI] [PubMed] [Google Scholar]
- [52].Perfume G, Nabhen SL, Barrera KR, Otero MG, Bianciotti LG, Vatta MS, Otero G, Long-term modulation of tyrosine hydroxylase activity and expression by endothelin-1 and -3 in the rat anterior and posterior hypothalamus., Am. J. Physiol. Regul. Integr. Comp. Physiol. 294 (2008) R905–14. 10.1152/ajpregu.00555.2007 [DOI] [PubMed] [Google Scholar]
- [53].Gras E, Belaidi E, Briançon-Marjollet A, Pépin J-L, Amaud C, Godin-Ribuot D, Endothelin-1 mediates intermittent hypoxia-induced inflammatory vascular remodeling through HIF-1 activation., J. Appl. Physiol. 120 (2016) 437–443. 10.1152/japplphysiol.00641.2015 [DOI] [PubMed] [Google Scholar]
- [54].Lenartowski R, Goc A, Epigenetic, transcriptional and posttranscriptional regulation of the tyrosine hydroxylase gene., Int. J. Dev. Neurosci. 29 (2011) 873–883. 10.1016/j.ijdevneu.2011.07.006 [DOI] [PubMed] [Google Scholar]
- [55].Morawietz H, Wagner AH, Hecker M, Goettsch W, Endothelin receptor B-mediated induction of c-jun and AP-1 in response to shear stress in human endothelial cells., Can. J. Physiol. Pharmacol. 86 (2008) 499–504. 10.1139/Y08-026 [DOI] [PubMed] [Google Scholar]
- [56].Nakashima A, Kodani Y, Kaneko YS, Nagasaki H, Ota A, Proteasome-mediated degradation of tyrosine hydroxylase triggered by its phosphorylation: a new question as to the intracellular location at which the degradation occurs, J. Neural Transm. 125 (2016) 9–15. 10.1007/s00702-016-1653-z [DOI] [PubMed] [Google Scholar]
- [57].Tank AW, Xu L, Chen X, Radcliffe P, Sterling CR, Post-transcriptional regulation of tyrosine hydroxylase expression in adrenal medulla and brain., Ann. N. Y. Acad. Sci. 1148 (2008) 238–248. 10.1196/annals.1410.054 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [58].Yao T, Ndoja A, Regulation of gene expression by the ubiquitin-proteasome system, Semin. Cell Dev. Biol. 23 (2012) 523–529. 10.1016/j.semcdb.2012.02.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [59].Kawahata I, Ohtaku S, Tomioka Y, Ichinose H, Yamakuni T, Dopamine or biopterin deficiency potentiates phosphorylation at 40Ser and ubiquitination of tyrosine hydroxylase to be degraded by the ubiquitin proteasome system, Biochem. Biophys. Res. Commun. 465 (2015) 53–58. 10.1016/j.bbrc.2015.07.125 [DOI] [PubMed] [Google Scholar]
- [60].Tekin I, Roskoski R, Carkaci-Salli N, Vrana KE, Complex molecular regulation of tyrosine hydroxylase., J. Neural Transm. 121 (2014) 1451–1481. 10.1007/s00702-014-1238-7 [DOI] [PubMed] [Google Scholar]
- [61].Vaiou M, Pangou E, Liakos P, Sakellaridis N, Vassilopoulos G, Dimas K, Papandreou C, Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity, J. Cancer Res. Clin. Oncol. 142 (2016) 2141–2158. 10.1007/s00432-016-2216-2 [DOI] [PubMed] [Google Scholar]
- [62].Kern RC, Foster JD, Pitovski DZ, Mineralocorticoid (type I) receptors in the olfactory mucosa of the mammal: studies with [3H]aldosterone and the anti-mineralocorticoid spironolactone., Chem. Senses. 22 (1997) 141–148. 10.1093/chemse/22.2.141 [DOI] [PubMed] [Google Scholar]
- [63].Weiler E, Deutsch S, Apfelbach R, Combined behavioral and c-Fos studies elucidate the vital role of sodium for odor detection., Chem. Senses. 31 (2006) 641–647. 10.1093/chemse/bjl004 [DOI] [PubMed] [Google Scholar]